EXHIBIT 12.1

			Ratio of Earnings to Fixed Charges
			(dollars in thousands, except ratio data)
			Year Ended December 31,
			2002			2001			2000			1999			1998
Fixed Charges:
		Interest expense on indebtedness(including amortization of debt expense and discount)	$	23,746		$	24,638		$	22,088		$	4,330		$	207
		Interest expense on portion of rent expense representative of interest		7,206			6,159			3,251			2,951			1,299
	Total Fixed Charges		$	30,952		$	30,797		$	25,339		$	7,281		$	1,506
Earnings (Loss):
		Net loss before provision for income taxes and cumulative effect of change in accounting principle	$	(219,716	)	$	(117,152	)	$	(235,331	)	$	(41,944	)	$	(22,957	)
		Fixed Charges per above		30,952			30,797			25,339			7,281			1,506
	Total Earnings (Loss)		$	(188,764	)	$	(86,355	)	$	(209,992	)	$	(34,663	)	$	(21,451	)
Ratio of Earnings to Fixed Charges				—			—			—			—			—
Coverage deficiency (1)(2)(3)			$	(219,716	)	$	(117,152	)	$	(235,331	)	$	(41,944	)	$	(22,957	)

(1)	The Company’s Coverage deficiency for 2002 includes charges aggregating $46,396 arising from the Company’s impairment charge relating to its investment in CAT and a charge for construction design changes of $32,158 and $14,238, respectively.
(2)	The Company’s Coverage deficiency for 2001 includes charges aggregating $26,208 arising from the Company’s impairment charge relating to its investment in Transgene and debt conversion expenses of $22,314 and $3,894, respectively.
(3)	The Company’s Coverage deficiency for 2000 includes charges aggregating $184,868 arising from purchased in-process research and development and debt conversion expenses of $134,050 and $50,818, respectively.